Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TRPYS
ADC Name
Anti-GPC3 ADC
Synonyms
Anti GPC3 ADC
   Click to Show/Hide
Drug Status
Investigative
Antibody Name
Anti-GPC3 mAb
  Antibody Info 
Antigen Name
Glypican-3 (GPC3)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 98
%
Hepatocellular carcinoma PDX model (PDX: LI1097)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Hepatocellular carcinoma PDX model (PDX: LI1037)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Hepatocellular carcinoma PDX model (PDX: LI1068)
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98% High GPC1 expression(GPC1+++)
Method Description
Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model Hepatocellular carcinoma PDX model (PDX: LI1097)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% High GPC1 expression(GPC1+++)
Method Description
Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model Hepatocellular carcinoma PDX model (PDX: LI1037)
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% High GPC1 expression(GPC1+++)
Method Description
Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model Hepatocellular carcinoma PDX model (PDX: LI1068)
References
Ref 1 A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human. Biopharm Drug Dispos. 2020 Nov;41(8-9):319-333. doi: 10.1002/bdd.2249. Epub 2020 Aug 19.